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Abstract 
Hereditary hemochromatosis (HFE) variants correlating with body iron levels have shown 
associations with cancer risk, including childhood acute lymphoblastic leukemia (ALL). Using a 
multi-ethnic sample of cases and controls from Houston, TX, we examined two HFE variants 
(rs1800562 and rs1799945), one transferrin receptor gene (TFRC) variant (rs3817672) and three 
additional iron-regulatory gene (IRG) variants (SLC11A2 rs422982; TMPRSS6 rs855791 and 
rs733655) for their associations with childhood ALL. Being positive for either of the HFE 
variants yielded a modestly elevated odds ratio (OR) for childhood ALL risk in males (1.40, 95% 
CI = 0.83 to 2.35), which increased to 2.96 (95% CI = 1.29 to 6.80) in the presence of a 
particular TFRC genotype for rs3817672 (Pinteraction= 0.04). The TFRC genotype also showed an 
ethnicity-specific association, with increased risk observed in non-Hispanic Whites (OR = 2.54, 
95% CI = 1.05 to 6.12; Pinteraction with ethnicity = 0.02). The three additional IRG SNPs all 
showed individual risk associations with childhood ALL in males (OR = 1.52 to 2.60). A 
polygenic model based on the number of variant alleles in five IRG SNPs revealed a linear 
increase in risk among males with the increasing number of variants possessed (OR = 2.0 per 
incremental change, 95% CI = 1.29 to 3.12; P = 0.002). Our results replicated previous HFE risk 
associations with childhood ALL in a US population and demonstrated novel associations for 
IRG SNPs, thereby strengthening the hypothesis that iron excess mediated by genetic variants 
contributes to childhood ALL risk. 
 
1. Introduction 
The hereditary hemochromatosis gene, HFE, has shown multiple associations with cancer 
susceptibility [1-7], including risk for childhood acute lymphoblastic leukemia (ALL) [8], which 
has been replicated [9]. In multiple cancers [1,2], including childhood ALL [9], the association 
of HFE variants with cancer risk gets stronger in interaction with a polymorphism in the 
transferrin receptor gene (TFRC). Since HFE and TFRC proteins biologically interact in iron 
transfer across membranes such as intestinal mucosa and placenta, the observed statistical 
interaction supports the notion that the involvement of HFE variants in cancer risk modification 
is mediated via their effect on body iron levels [10]. Body iron levels have long been known to 
be positively correlated with general cancer risk as several cohort studies have shown [11-14], 
and iron’s carcinogenic effect has been well documented [15]. Thus, HFE associations with 
cancer have strong biological plausibility.   
 Recent genome-wide association studies (GWAS) have identified the HFE variant 
C282Y as a major determinant of body iron levels [10]. The mediation of iron homeostasis by 
genetic variants extends beyond the HFE gene, with the strongest association being TMPRSS6 
rs855791 [16]. We reasoned that if HFE associations are due to their effect on iron levels rather 
than linkage disequilibrium with nearby polymorphisms, other iron regulatory gene (IRG) 
polymorphisms should show similar associations with childhood ALL risk. To test our 
hypothesis that previously observed HFE associations are mediated via their effect on body iron 
levels, we aimed to expand our study beyond HFE variants to additional IRG polymorphisms, 
first by confirming previously shown HFE SNP associations with childhood ALL, and assessing 
novel SNPs in TMPRSS6 and SLC11A2 for their associations. To further test our hypothesis that 
HFE variants modify the risk for childhood ALL via their effects on iron levels, we also included 
the TFRC polymorphism that is known to interact with HFE variants in the genotyping scheme 
to test whether this interaction occurs. The additional IRGs do not interact with TFRC 
biologically, so we did not predict any other interaction. To test our hypothesis, we used a new 
case-control set, which was first validated by replicating known childhood ALL associations 
[17].  
 
2. Subjects & Methods 
2.1 Subjects 
Institutional Review Boards of Baylor College of Medicine (BCM) and Florida 
International University approved the study protocol. The case-control sample was from 
Houston, TX, consisting of 161 incident cases with childhood (<18 years at diagnosis) ALL 
diagnosed at Texas Children’s Hospital from 2007 to 2012, and 231 healthy controls with the 
same age range (<18 yr) contemporaneously and locally recruited. Thus, all subjects were less 
than 18 years of age, and exclusion criteria for both cases and controls were refusal to participate 
in the study and the diagnosis of any other cancer or disease. Representing the age peak typical 
of childhood ALL, 73% of cases were 1 to 5 years old. Subjects and their parents were 
approached to obtain informed consent for provision of epidemiological data with a 
questionnaire and a biological sample. The DNA samples were extracted from saliva or 
peripheral blood samples at BCM. The sample was multiethnic to allow us to examine effect 
modification of childhood ALL risk by ethnicity. Ethnicity was determined by the responses 
provided on the questionnaire by the children’s parents. Our main interest was the contrast 
between non-Hispanic Whites (NHW) and Hispanic Whites (HW), since childhood ALL is very 
rare in African-Americans, and we had a very small number of African-Americans (n=17) in the 
case group. Information on clinical subtype of ALL was collected from medical records, and 
88% of the cases were diagnosed with early precursor B (early pre-B) ALL subtype. 
2.2 SNP selection 
We included two HFE variants known to influence body iron levels commonly known as 
C282Y (rs1800562) and H63D (rs1799945), as well as the TFRC variant S142G (rs3817672), 
which is known to interact with HFE variants in previously reported cancer associations [1,2,9]. 
As other IRG variants, we included the GWAS-identified iron-related SNP TMPRSS6 rs855791 
[16], as well as two additional SNPs we selected also from the TMPRSS6 gene (rs733655) and 
the SLC11A2 gene (rs422982) involved in the non-transferrin receptor-related iron transfer 
across membranes. The last two SNPs were selected as the promoter region haplotype tagging 
SNPs for these two genes. The selected SNP from TMPRSS6 (rs733655) is 32kb away and not in 
linkage disequilibrium with the GWAS-identified marker (rs855791) in the same gene according 
to the HapMap project European population data (r2 = 0.29). Two more SNPs were included as 
ancestry-informative markers (AIMs) to adjust for the ethnic heterogeneity in the multiethnic 
sample to supplement the self-reported ethnicity data. The two SNPs were rs285 and rs2891, 
which were identified as AIMs in previous studies due to their largely different allele frequencies 
in major ancestral human populations [18,19]. Characteristics of each SNP are given in Table I. 
2.3 Genotyping 
TaqMan allelic discrimination assay was the choice of method for genotyping. All SNPs 
were genotyped by TaqMan assays purchased from Life Technologies (Foster City, CA) on 
CFX96 real-time PCR instrument (Bio-Rad, Hercules, CA). The assay ID of each assay is given 
in Table I. 
2.4 Statistical analysis 
Genetic associations (both crude and adjusted) were evaluated by logistic regression 
using Stata v.11 (StataCorp, College Station, TX). Two-way statistical interactions were also 
analyzed by logistic regression by including an interaction (product) term for the genetic variant 
and the potential effect modifier (age, gender or ethnicity) in the explanatory variables in 
multivariable analysis. All statistical tests were two-tailed and threshold for statistical 
significance was set at P ≤ 0.05. All genetic associations, except the TFRC locus, were assessed 
by using the dominant genetic model which corresponds to variant allele positivity and coded as 
1 for heterozygote and variant allele homozygote genotypes, and 0 for the common allele 
homozygosity (referent). Due to the low frequency of their variant alleles, the two HFE SNPs 
were pooled together by creating a new variable for the number of cumulative variant alleles at 
both SNPs (0 for no variant allele, 1 for variant allele at either SNP, 2 for heterozygosity at both 
SNPs (compound heterozygosity) or variant allele homozygosity at either SNP). To be consistent 
with the previous studies, TFRC SNP was analyzed in recessive model (by coding variant allele 
homozygosity as 1 and the other genotypes as 0). A similar approach was used for a polygenic 
risk model using the total number of variant alleles at two HFE variants and three variants in 
non-HFE (TMPRSS6, SLC11A2) IRGs (0 for no variant allele at any SNP, 1 for one or two 
variant alleles at any SNP, 2 for three or more variant alleles at any of the five SNPs). All 
statistical associations in the overall group were adjusted for the ethnicity variable which had 
four categories (NHW, HW, African-Americans, and others). The efficiency of statistical 
adjustment for ethnicity was double-checked by adjustment for each of the AIMs separately. 
Before proceeding to the statistical analysis of genetic associations, Hardy-Weinberg 
disequilibrium was ruled out in controls as a test for gross genotyping errors. Given the number 
of associations examined, we used a slightly more stringent statistical significance threshold of P 
≤ 0.01 in the interpretation of our results. 
 
3. Results 
3.1 HFE C282Y and H63D frequencies in the sample population 
As expected, HFE C282Y mutation was more common in the NHW subjects: variant 
allele frequencies were 0.113, 0.030 and 0.011 in NHWs, HWs, and African-Americans, 
respectively. The H63D variant positivity also had some variation across ethnic groups with 
frequencies of 0.254, 0.151 and 0.032 in NHWs, HWs, and African-Americans, respectively. 
These variations were similar to those observed in HapMap project population samples. Only 
two cases and two controls (all NHWs) were compound heterozygotes for C282Y and H63D.  
3.2 Univariable genetic marker analyses in the overall group 
Genotype frequencies for each SNP were in Hardy-Weinberg equilibrium in the control 
group when analyzed for each ethnicity group. All associations reported below for the whole 
group were adjusted for self-reported ethnicity. Replacing the ethnicity variable by either AIM 
did not appreciably alter the results. As shown in Table II, neither C282Y nor H63D showed an 
overall association with childhood ALL risk. The TFRC SNP, which was included in the study to 
assess its interaction with HFE SNPs did not show any individual association in the overall 
group. The three IRG variants all yielded high ORs in the overall analysis, but only one 
(rs733655) reached statistical significance in the overall analysis (Table II).  
3.3 Gender- and ethnicity-specific analyses and statistical interactions 
For the two TMPRSS6 SNPs, males had risk associations with ORs of 1.91 and 2.60 
(Table III), but statistical interaction with gender did not reach statistical significance. Despite 
yielding greater ORs for males, the male-specific HFE associations did not reach statistical 
significance in individual analysis. Results from pooling of the two HFE variants in one variable 
(as described in the Methods) are shown in Figure I. The bars depict the risk genotype 
frequencies in the case and control groups, and ORs for childhood ALL risk are provided. There 
was no statistically significant association in the overall group (OR = 1.46, P = 0.17; Graph A in 
Figure I), but the pooled variable revealed a promising result in males (OR = 2.09, P = 0.04; 
Graph B in Figure I), which reached statistical significance in interaction with the TFRC variant 
(OR = 4.92, P = 0.002; Graph D in Figure I). Graph C depicts the frequencies and OR for female 
cases/controls, and Graph E shows the frequencies and OR for males with the wild type allele for 
TFRC. 
We explored the TFRC and HFE gene-gene interactions previously observed in multiple 
cancers [1,2], including childhood ALL [9]. In the overall sample, there was no interaction (data 
not shown). Our main group of interest was males because of the previous findings in childhood 
ALL, and also because of generally higher ORs in males in univariable analysis of HFE variants. 
Since the small sample size would not allow a reliable assessment of interactions for rare HFE 
variants, especially C282Y, we used the HFE pooled variant variable for this analysis. In the two 
groups of males with and without the TFRC homozygous genotypes, the ORs were 0.59 (CI = 
0.24 to 1.45) and 4.92 (CI = 1.29 to 6.80), yielding an interaction (Pinteraction= 0.04). We also 
examined interactions of non-HFE SNPs with TFRC. This analysis did not reveal any interaction 
(P = 0.33, 0.46, and 0.96) as expected from the lack of biological interaction between these IRGs 
and TFRC.  
There was no ethnicity-specific association of HFE variants. Ethnicity-specific analyses 
revealed a high OR (2.54, CI= 1.05 to 6.12, P value = 0.04) for the TFRC rs3817672 allele A 
homozygote genotype in NHWs, while the OR was less than 1.0 (non-significant) in Hispanics 
(Pinteraction = 0.02 for ethnicity). Thus, the largest ethnicity-specific difference was the NHW-
specific association of TFRC with borderline statistical significance. The association of the 
TMPRSS6 promoter region tagging SNP rs733655 was equally strong in both ethnicities that 
could be examined in this study (ORs 2.32 and 2.55; Table III). 
3.4 Polygenic risk model 
We constructed a polygenic risk variable consisting of five SNPs in three IRGs as 
described in the Methods section. Analysis using this variable showed that for stepwise increase 
in the number of variant alleles, there was a linear increase in childhood ALL risk in the overall 
group (OR = 1.63, 95% CI = 1.18 to 2.26, P = 0.003), and in males (OR = 2.00, 95% CI = 1.29 
to 3.12, P = 0.002; shown in Figure II), but not in females (OR = 1.26, 95% CI = 0.77 to 2.08, P 
= 0.36) in stratified analyses. In ethnicity-specific analysis, the association remained statistically 
significant in NHW (OR = 2.19, 95% CI = 1.18 to 4.06, P = 0.01), but not in HW (OR = 1.42, 
95% CI = 0.89 to 2.27, P = 0.14).  
None of the associations were lost when we restricted the analysis to early pre-B subtype 
or the cases within the age peak. All associations observed in the whole group were also 
statistically significant in these subgroups sometimes with greater effect size (data not shown).  
 
4. Discussion 
We examined previously reported HFE associations and interactions with TFRC with the 
risk of childhood ALL. In this multi-ethnic sample, we observed associations similar to 
previously reported ones with gender effect, and extended the observations to additional iron 
regulatory gene polymorphisms to provide further support for our hypothesis that HFE and 
TFRC association in childhood ALL is due to their effect on iron homeostasis. The only 
statistically significant gender-specific associations with IRG variants and childhood ALL risk 
were in males, and we also noted a novel ethnicity-specific difference in the association of the 
TFRC variant.  
To increase statistical power, we pooled the two HFE variants to be able to detect their 
associations with childhood ALL risk. The ORs for the pooled variables were always in the risk 
direction for individual SNPs, and were greater in males. When the interaction with the TFRC 
genotype and the gender effect was considered, a more robust association was found, as in a 
previous study [9]. The same interaction was also observed in multiple cancers [1,2] and in 
childhood ALL. While interaction analysis is usually seen as a challenge in terms of statistical 
power, as happened in the present study, the increase in the effect size may compensate for the 
loss of statistical power due to comparison of smaller subsets of the sample. Like any statistical 
association, our results should be considered cautiously. However, similarities with previous 
observations provide sufficient credibility to the cumulative results, which now strongly suggest 
that iron excess, whether environmentally- or genetically-induced, increases the risk for cancer in 
general, and in particular for childhood ALL. As previously postulated [9,20], the mechanism of 
the childhood ALL risk association with HFE variants known to elevate body iron levels may 
include increased materno-fetal iron transport through placenta. This process is mediated by 
HFE and TFRC [21,22], and these genetically-mediated alterations in fetal iron homeostasis may 
also have implications on the developmental origins of health and disease [23].  
 Another novel finding of the present study was the risk associations of previously 
unexamined IRG SNPs (rs422982 and rs733655) with childhood ALL. Together with the 
association of rs855791, a GWAS identified marker for iron levels [16], which reached statistical 
significance only in males, these new findings lend support to our hypothesis that iron 
homeostasis related risk modification in childhood ALL extend beyond HFE/TFRC 
polymorphisms. We do not yet know whether the SNPs selected by us and used in any 
association study for the first time have any correlation with body iron levels. Their locations in 
the promoter regions of crucial IRGs suggest that they will be somewhat involved in some aspect 
of gene function and subsequently in iron homeostasis, but only functional studies can confirm 
their roles. We were not surprised by the lack of interaction between SLC11A2 / TMPRSS6 and 
TFRC since they do not interact biologically. The lack of statistical interaction between these 
additional SNPs and the TFRC SNP suggested the specificity of the observed HFE and TFRC 
interaction.  
The present study highlights the benefits of explorations of effect modification by gender 
or ethnicity. Although such explorations are usually reserved for well powered studies, when 
backed up by previous observations or strong biological hypotheses, stratified analyses 
complemented by statistical interaction analyses are powerful approaches to unravel otherwise 
masked associations. It is only natural that in a multigenic disorder like cancer, effect 
modification will be operational. Researchers usually shy away from analysis of effect 
modification or statistical interaction to avoid performing multiple comparisons and subsequent 
chance findings, but there are ways to rule out chance findings by additional replication studies.  
Besides the limitations already mentioned such as sample size and statistical power, our 
study has another limitation, which has stemmed from one of its strengths. Examination of these 
associations in a multi-ethnic cohort has benefits, but also brings about heterogeneity, which 
should be accounted for during analysis. We had self-reported ethnicity data, but adjustment of 
the results by these data may still leave some residual confounding. We also used two AIMs to 
make sure that the heterogeneity in the population would not result in spurious findings. The 
current practice in well-resourced GWAS studies is to use thousands of AIMs to adjust for 
genetic ancestry, which is particularly crucial when the sample includes recently admixed 
populations such as African Americans or Hispanics. We could not do that, but could include 
two AIMs to control for population heterogeneity. Another limitation of using a multi-ethnic 
sample was the constraints it adds on checking genotyping error. We followed the usual 
safeguards of genotyping error avoidance at the experimental phase, and checked for errors at the 
analysis phase by using Hardy-Weinberg equilibrium testing. This test, however, has to be done 
in each ethnicity subgroup separately. This practice further reduces the statistical power of this 
test and may have caused inefficiency of genotyping error checking. Genotyping errors have the 
potential to cause both false positives and false negatives. Our results basically replicated 
previously observed associations, and there is no overwhelming reason to consider genotyping 
errors as an alternative explanation.  
By mainly replicating the HFE and TFRC interaction in childhood ALL risk association 
and revealing new associations with IRGs, we provided further support for the hypothesis on the 
iron connection in childhood ALL susceptibility. These findings have far reaching implications 
beyond childhood leukemia in the cancer field. We hope that our results will stimulate interest in 
secondary analyses of existing GWAS data on multiple cancers to explore the pathways involved 
in iron homeostasis. We also report novel associations with gender or ethnicity specificity. These 
associations should be explored in already existing datasets for replication. Beyond genetic 
association studies, functional work on whether these polymorphisms indeed mediate placental 
iron transport and whether this effect differs by gender will provide ultimate confirmation of our 
results with translational implications. 
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Table I. Main features of SNPs analyzed 
 
*Genome Reference Consortium Human Build 37 patch release 10 (GRCh37.p10) used for nucleotide position 
(http://www.ncbi.nlm.nih.gov/SNP) 
Gene SNP 
Chromosome 
nucleotide position* 
Minor allele and 
frequency† 
SNP Type Assay ID 
HFE rs1800562 chr6: 26093141 (A) 0.053  
Transition substitution, 
missense mutation 
C___1085595_10 
HFE rs1799945 chr6: 26091179 (G) 0.179  
Transversion substitution,  
missense mutation 
C___1085600_10 
TFRC rs3817672 chr3: 195800811 (G) 0.383  
Transition substitution, 
missense mutation 
C___3259537_10 
SLC11A2 rs422982 chr12: 51406354 (A) 0.246  
Transversion substitution, 
intragenic 
C____570333_10 
TMPRSS6 rs733655 chr22: 37495051 (C) 0.221  
Transition substitution, 
intragenic 
C___3289858_1_ 
TMPRSS6 rs855791 chr22: 37462936 (T) 0.412  
Transition substitution, 
missense mutation 
C___3289902_10 
LPL rs285 chr8: 19815189 (T) 0.500  
Transition substitution, 
intragenic 
C__12104266_10 
ITGAE rs2891 chr17: 3705526 (G) 0.496  
Transition substitution, 
intragenic 
C___3211308_20 
†Minor allele frequencies are from a reference Caucasian population (U.S. residents of northern and western European ancestry) 
genotyped in HapMap project   
  
Table II. Univariable analyses of associations with childhood ALL risk* 
 
SNP 
OR 
(95% CI) 
P value 
HFE rs1800562 
1.37 
(0.52 to 3.60) 
0.52 
HFE rs1799945 
1.33 
(0.74 to 2.38) 
0.35 
TFRC rs3817672 
0.8 
(0.52 to 1.23) 
0.31 
SLC11A2 rs422982 
1.55 
(1.01 to 2.37) 
0.04 
TMPRSS6 rs733655 
2.06 
(1.33 to 3.20) 
0.001 
TMPRSS6 rs855791 
1.41 
(0.91 to 2.18) 
0.12 
 
*Adjusted for self-reported ethnicity (non-Hispanic White, Hispanic White, African-Americans, 
and others) 
 
  
 Table III. HFE and non-HFE associations with childhood ALL in gender and 
ethnicity groups (ORs and 95% CIs) 
 
  
Females 
(n=176) 
Males 
(n=216) 
Non-Hispanic 
Whites 
(n=115) 
Hispanic Whites 
(n=170) 
HFE rs1800562 
0.40 
(0.08 to 1.89) 
P = 0.25   
3.41 
(0.86 to 13.52) 
P = 0.08 
1.78 
(0.51 to 6.14) 
P = 0.36     
0.91 
(0.15 to 5.58) 
P = 0.92 
  Pinteraction = 0.09 Pinteraction = 0.55 
HFE rs1799945 
1.01 
(0.41 to 2.48) 
P = 0.98 
1.51 
(0.69 to 3.31) 
P = 0.30       
1.26 
(0.53 to 2.99) 
P = 0.60 
0.87 
(0.37 to 2.08) 
P = 0.76       
  Pinteraction = 0.78 Pinteraction = 0.56 
TFRC rs3817672 
1.66 
(0.71 to 3.86) 
P = 0.24 
0.7 
(0.31 to 1.57) 
P = 0.38 
2.54 
(1.05 to 6.12) 
P = 0.04 
0.69 
(0.37 to 1.27) 
P = 0.23      
  Pinteraction = 0.21 Pinteraction = 0.02 
SLC11A2 rs422982 
1.58 
(0.83 to 2.99) 
P =  0.17 
1.52 
(0.86 to 2.68) 
P = 0.15 
1.47 
(0.70 to 3.10) 
P = 0.31 
1.91 
(0.99 to 3.68) 
0.055      
  Pinteraction = 1.00 Pinteraction = 0.61 
TMPRSS6 rs733655 
1.56 
(0.81 to 3.03) 
P = 0.19      
2.6 
(1.44 to 4.70) 
P = 0.002 
2.35 
(1.07 to 5.16) 
P = 0.03 
2.52 
(1.26 to 5.04) 
P = 0.009 
  Pinteraction = 0.19 Pinteraction = 0.90 
TMPRSS6 rs855791 
1.12 
(0.58 to 2.14) 
P = 0.74 
1.91 
(1.04 to 3.51) 
P = 0.04 
1.71 
(0.78 to 3.72)  
P = 0.18 
1.22 
(0.62 to 2.38) 
P = 0.57 
  Pinteraction = 0.40 Pinteraction = 0.52 
 
*Adjusted for self-reported ethnicity (non-Hispanic white, Hispanic white, African-Americans, 
and others) 
 
  
 
 
 
 
 
 
 
 
 
 
Figure I: Risk genotype frequencies and pooled HFE association in childhood ALL in case 
and control groups, by gender and TFRC genotype group.  
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      Figure II: Polygenic risk variable consisting of five IRG SNPs  
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